跳至主要内容
临床试验/ACTRN12623000135617
ACTRN12623000135617尚未招募未知

Pilot Study- Assessment of the usefulness of Fibroblast Activation Protein Inhibitor Positron Emission Tomography (FAPI PET) in Castrate Resistant Prostate Carcinoma patients with discordant disease at fluorodeoxyglucose Positron Emission Tomography (FDG PET)

Mercy Radiology0 个研究点目标入组 10 人开始时间: 2023年2月8日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Male

入选标准

  • Patient age >= 18 years.
  • All patients diagnosed with Castrate Resistant Prostate Cancer referred for 177Lu-PSMA therapy, undergoing or having undergone assessment for discordant disease within 3 months from baseline
  • Able to give informed consent
  • Willing to use effective contraceptive methods for the duration of the study

排除标准

  • Pts with confirmed disease who have not had [18F]FDG PET CT and 68Ga-PSMA
  • Patients unable, or unwilling to consent
  • Unwilling to use contraceptive methods

研究者

相似试验

Pilot Study – Role of Fibroblast Activation Protein... | 临床试验